Insider information
16.01.2023 10:40:01 (local time)
Company: Sopharma AD-Sofia (SFA)
Sopharma AD received a corrected tender offer, registered with the Financial Supervision Commission from Donev Investments Holding AD - a shareholder directly owning 37,600,000 shares, representing 27.89% of the capital and votes in the GMS of Sopharma AD on the grounds of Art. 149b of the POSA.
The main conditions of the tender offer are:
The tenderer is Donev Investments Holding AD, UIC 831915121, LEI code 529900M68G247LNXVB33.
Donev Investments Holding AD does not own (directly, through related parties or indirectly under Art. 149 (2) of the POSA) 89,865,700 shares /66.67%/ of the capital of Sopharma AD.
According to the decision taken by the offeror's Board of Directors dated October 28, 2022, the offeror intends to
increase its share in the company's capital by acquiring directly and through related parties more than 1/3, namely - up to 41.49% of the votes in the General Meeting of the company's shareholders by purchasing via tender offer under Art. 149b of the POSA, addressed to all other shareholders of Sopharma AD, of up to 11,000,000 ordinary shares representing 8.16% of the capital and votes in the General Meeting of Shareholders of Sopharma AD.
The proposed price of the tender offer is BGN 4.50 per share and is higher than the average weighted market price per share for the last six (6) months before the registration of the tender offer, which is BGN 4.485.
Each shareholder and addressee of the proposal can accept it within the specified period by applying for acceptance according to the model. The tender offeror shall pay the price of the purchased shares through Karoll AD Investment Intermediary within seven (7) working days upon expiry of the period for accepting the offer, following the payment instructions by the respective shareholder.
The Financial Supervision Commission has not taken a position on the submitted corrected draft of the tender offer.
Please, refer to the entire piece of news in English on the financial website X3News.
Sopharma AD published this content on 16 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 January 2023 09:49:04 UTC.
Sopharma AD, formerly Sopharma AD Sofia, is a Bulgaria-based company engaged in the generic pharmaceutical industry. The Company specializes in the production and trade of medical substances and finished drug forms, as well as research and development in the field of medical products. Through the ampoule plant, tablet plant and the plant in Vrabevo it produces medicines, such as analgesics, antipyretics, cardiovascular medicines as well as drugs for respiratory disease treatment, among others. The Company offers its products under the brand Tribestan, Nivalin and Tabex, among others. In addition, it specializes in the gamma-sterilization of medical materials. It is the parent company of Sopharma Group and operates domestically and abroad in such countries as Russian Federation, Poland, Ukraine, Serbia, the United States and the United Kingdom, among others.
SOPHARMA AD 
